single-cell genomics

Fluidigm's product revenues are expected to grow 27 percent annually over the next four years, buoyed by the company's participation in three rapidly growing niche markets — sample preparation for next-gen sequencing, single-cell genomics, and digital PCR — according to a market

This article has been updated from a previous version to include market research information about Fluidigm from DeciBio.

Just ahead of announcing its first-quarter financial results, Fluidigm this week disclosed the end of one partnership and the beginning of another, with the net result being a de-emphasis of its digital PCR technology for molecular diagnostics and a continued emphasis on single-c

By Molika Ashford

By Ben Butkus

By Ben Butkus